Javascript must be enabled to continue!
IL-21-STAT3 axis negatively regulates LAIR1 expression in B cells
View through CrossRef
AbstractLAIR1 is an inhibitory receptor broadly expressed on human immune cells, including B cells. LAIR1 has been shown to modulate BCR signaling, however, it is still unclear whether its suppressive activity can be a negative regulator for autoreactivity. In this study, we demonstrate the LAIR1 expression profile on human B cells and prove its regulatory function and relationships to B cell autoreactivity. We show that both the frequency and level of LAIR1 expression decreases during B cell differentiation. LAIR1 expressing (LAIR1+) switched memory (SWM) B cells have a transcriptional profile less differentiated toward a plasma cell (PC) phenotype, harbor more autoreactive B cells and exhibit less PC differentiationin vitrothan the LAIR1 negative (LAIR1-) counterpart. These data suggests that LAIR1 functions as a B cell tolerance checkpoint. We confirm previous data showing that patients with systemic lupus erythematosus (SLE) express less LAIR1 on B cells, implying a breakdown of the checkpoint, consistent with the enhanced PC differentiation seen in SLE. We further demonstrate that LAIR1 expression is down-regulated through the IL-21/STAT3 pathway which is known to be upregulated in SLE. These data suggest therapeutic targets that might decrease the aberrant PC differentiation observed in SLE.
Cold Spring Harbor Laboratory
Title: IL-21-STAT3 axis negatively regulates LAIR1 expression in B cells
Description:
AbstractLAIR1 is an inhibitory receptor broadly expressed on human immune cells, including B cells.
LAIR1 has been shown to modulate BCR signaling, however, it is still unclear whether its suppressive activity can be a negative regulator for autoreactivity.
In this study, we demonstrate the LAIR1 expression profile on human B cells and prove its regulatory function and relationships to B cell autoreactivity.
We show that both the frequency and level of LAIR1 expression decreases during B cell differentiation.
LAIR1 expressing (LAIR1+) switched memory (SWM) B cells have a transcriptional profile less differentiated toward a plasma cell (PC) phenotype, harbor more autoreactive B cells and exhibit less PC differentiationin vitrothan the LAIR1 negative (LAIR1-) counterpart.
These data suggests that LAIR1 functions as a B cell tolerance checkpoint.
We confirm previous data showing that patients with systemic lupus erythematosus (SLE) express less LAIR1 on B cells, implying a breakdown of the checkpoint, consistent with the enhanced PC differentiation seen in SLE.
We further demonstrate that LAIR1 expression is down-regulated through the IL-21/STAT3 pathway which is known to be upregulated in SLE.
These data suggest therapeutic targets that might decrease the aberrant PC differentiation observed in SLE.
Related Results
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract
Background The STAT3 pathway may drive prostate cancer (PCa) progression to metastatic castration-resistant prostate cancer (mCRPC). STAT3 may serve as a go...
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract
Approximately 13% of women are diagnosed with invasive breast cancer. Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor t...
Abstract 4699: Single domain antibody (sdAb) localizes in cancer cells to inhibit signal transducer and activator of transcription 3 (STAT3) resulting in therapeutic inhibition of multiple cancers
Abstract 4699: Single domain antibody (sdAb) localizes in cancer cells to inhibit signal transducer and activator of transcription 3 (STAT3) resulting in therapeutic inhibition of multiple cancers
Abstract
STAT3 is involved in the pathogenesis of many malignancies, so we developed an anti-STAT3 VHH (variable region of the heavy chain), SBT-100, that internaliz...
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Abstract
Abstract 2849
Poster Board II-825
Histone deacetylase inhibitors (HDACi) are emerging as a potential therapy for Multiple Myel...
Abstract 5436: Novel single-domain antibody (sdAb), SBT-100, localizes in the cytoplasm to inhibit IL-6 mediated P-STAT3 nuclear translocation in cancer cells
Abstract 5436: Novel single-domain antibody (sdAb), SBT-100, localizes in the cytoplasm to inhibit IL-6 mediated P-STAT3 nuclear translocation in cancer cells
Abstract
BACKGROUND: Interleukin-6 (IL-6) is a multifunctional cytokine that is involved in immune defense and plays an important role in biologic activities of cell...
Glycyrrhizin improves the pathogenesis of psoriasis through IL-17A and the SIRT1-STAT3 axis
Glycyrrhizin improves the pathogenesis of psoriasis through IL-17A and the SIRT1-STAT3 axis
Abstract
Background: The anti-inflammatory effect of glycyrrhizin has been widely recognized, while the specific mechanism of glycyrrhizin in psoriasis remains poorly under...
O18 Molecular crosstalk between PLCγ1 and STAT3 in cutaneous T-cell lymphoma
O18 Molecular crosstalk between PLCγ1 and STAT3 in cutaneous T-cell lymphoma
Abstract
Cutaneous T-cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes that is difficult to diagnose and treat due to a high degree of clin...
Intervening in the S1PR1/STAT3 Signaling Pathway Attenuates Valvular Damage Due to Rheumatic Heart Disease
Intervening in the S1PR1/STAT3 Signaling Pathway Attenuates Valvular Damage Due to Rheumatic Heart Disease
Abstract
Background: Rheumatic heart disease (RHD) affects many patients every year, but its pathogenesis is still unclear. Recent studies have found that the sphingosine 1...

